

Edgar Filing: ACAMBIS PLC - Form 6-K

ACAMBIS PLC  
Form 6-K  
May 15, 2007

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13s - 16 or 15d - 16 of  
the Securities Exchange Act of 1934

For the month of May 2007

Acambis plc  
(Translation of registrant's name into English)

Peterhouse Technology Park  
100 Fulbourn Road  
Cambridge CB1 9PT  
England

(address of principal executive offices)

(Indicate by check mark whether the registrant files or will file annual  
reports under cover of Form 20-F or Form 40-F

Forms 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934).

Yes  No

(if "Yes" is marked, indicate below the file number assigned to the registrant  
in connection with Rule 12g3-2(b): 82- ).

Enclosure:

FDA publishes documents

FDA publishes ACAM2000 Advisory Committee briefing documents and questions

Cambridge, UK and Cambridge, Massachusetts - 15 May 2007 - Acambis plc (Acambis)  
(LSE: ACM) announces that the ACAM2000-related briefing documents for the  
Vaccines and Related Biological Products Advisory Committee scheduled for  
Thursday, 17 May are now accessible via the US Food and Drug Administration's  
(FDA) website.

Briefing documents have been provided by the FDA and Acambis. The documents  
include details of the safety and efficacy data generated by Acambis through its  
clinical development programme.

This information can be accessed at <http://www.fda.gov/ohrms/dockets/ac/07/>

## Edgar Filing: ACAMBIS PLC - Form 6-K

briefing/2007-4292B2-00-index.htm.

Acambis developed ACAM2000 under contracts with the US Centers for Disease Control and Prevention in response to the US Government's need for a stockpile of smallpox vaccine to counter the threat of smallpox being used as a biological weapon. To date, Acambis has supplied 192.5 million doses of ACAM2000 to the US 's Strategic National Stockpile under an FDA Investigational New Drug application.

-ends-

Enquiries:

Acambis plc  
Ian Garland, Chief Executive Officer  
Elizabeth Brown, Acting Chief Financial Officer  
Lyndsay Wright, VP, Communications and IR  
Tel: +44 (0) 1223 275 300

Brunswick  
Jon Coles / Justine McIlroy / Margherita Lupi  
Tel: +44 (0) 20 7404 5959

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. ChimeriVax-JE, Acambis' most advanced product in the non-biodefence pipeline, has to date shown an excellent safety and efficacy profile following pivotal Phase 3 trials. It is currently undergoing paediatric trials in India and is partnered with sanofi pasteur and Bharat Biotech. Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at [www.acambis.com](http://www.acambis.com).

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see relevant risk sections in the Company's latest Annual Report and Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and

## Edgar Filing: ACAMBIS PLC - Form 6-K

difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant Peptide Therapeutics Group has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 15 May 2007

ACAMBIS PLC

By: /s/ Lyndsay Wright  
Name: Lyndsay Wright  
Title: VP, Communications and IR.